Alert icon

To align with industry best practices for security and data integrity, Project Data Sphere is requiring users to upgrade their browsers to one that supports encryption protocol TLS 1.2 by December 15, 2017. On that date, Project Data Sphere will disable support of browsers that permit SSL 3.0/TLS 1.0. To prevent any disruption to your access to Project Data Sphere, you must take action.
This browser was not recognized and may not be compatible with TLS 1.2 or higher. Please check with the browser's developer to confirm.
To view information about this, please visit the FAQ. If you have any further questions, please contact us.

Back to the List
Type(s) of Cancer
Study Phase
Phase 3
Study Completion Date
November 2009
NCT00384176Uploaded 08-29-2013
Available for Download
PDS UID: Colorec_AstraZe_2006_78
A Randomised, Double-blind, Multicentre Phase II/III Study to Compare the Efficacy of Cediranib (RECENTIN™, AZD2171) in Combination With 5-fluorouracil, Leucovorin, and Oxaliplatin (FOLFOX), to the Efficacy of Bevacizumab in Combination With FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer
PDS UID: Colorec_Multipl_2006_251Go to Study
Enhancing the Analytic Capacity of Colorec_AstraZe_2006_78 using a Statistical Linkage Method to Append Socioeconomic and Health Care Access Variables from the Medical Expenditure Panel Survey
PROTOCOLAstraZeneca Study Protocol Cediranib.pdf
CRFAstraZeneca CRF Cediranib.pdf
DATA (COMPARATOR ARM)AstraZeneca Data Cediranib.xls